1
|
Jésus P, Patin F, Bakkouche S, Beltran S, Andrès C, Vourc’h P, Blasco H, Corcia P. Corrélations entre les paramètres biologiques et la composition corporelle dans la sclérose latérale amyotrophique. NUTR CLIN METAB 2019. [DOI: 10.1016/j.nupar.2019.01.339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
2
|
Blasco H, Veyrat-Durebex C, Bocca C, Patin F, Vourc'h P, Kouassi Nzoughet J, Lenaers G, Andres CR, Simard G, Corcia P, Reynier P. Lipidomics Reveals Cerebrospinal-Fluid Signatures of ALS. Sci Rep 2017; 7:17652. [PMID: 29247199 PMCID: PMC5732162 DOI: 10.1038/s41598-017-17389-9] [Citation(s) in RCA: 97] [Impact Index Per Article: 13.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/13/2017] [Accepted: 11/22/2017] [Indexed: 12/30/2022] Open
Abstract
Amyotrophic lateral sclerosis (ALS), the commonest adult-onset motor neuron disorder, is characterized by a survival span of only 2–5 years after onset. Relevant biomarkers or specific metabolic signatures would provide powerful tools for the management of ALS. The main objective of this study was to investigate the cerebrospinal fluid (CSF) lipidomic signature of ALS patients by mass spectrometry to evaluate the diagnostic and predictive values of the profile. We showed that ALS patients (n = 40) displayed a highly significant specific CSF lipidomic signature compared to controls (n = 45). Phosphatidylcholine PC(36:4), higher in ALS patients (p = 0.0003) was the most discriminant molecule, and ceramides and glucosylceramides were also highly relevant. Analysis of targeted lipids in the brain cortex of ALS model mice confirmed the role of some discriminant lipids such as PC. We also obtained good models for predicting the variation of the ALSFRS-r score from the lipidome baseline, with an accuracy of 71% in an independent set of patients. Significant predictions of clinical evolution were found to be correlated to sphingomyelins and triglycerides with long-chain fatty acids. Our study, which shows extensive lipid remodelling in the CSF of ALS patients, provides a new metabolic signature of the disease and its evolution with good predictive performance.
Collapse
Affiliation(s)
- H Blasco
- Université François-Rabelais, Inserm, U930, Tours, France. .,Laboratoire de Biochimie, CHRU de Tours, France. .,Institut MITOVASC, UMR CNRS6015-INSERM1083, Université d'Angers, Angers, France.
| | - C Veyrat-Durebex
- Institut MITOVASC, UMR CNRS6015-INSERM1083, Université d'Angers, Angers, France.,Département de Biochimie et Génétique, CHU d'Angers, France
| | - C Bocca
- Institut MITOVASC, UMR CNRS6015-INSERM1083, Université d'Angers, Angers, France.,Département de Biochimie et Génétique, CHU d'Angers, France
| | - F Patin
- Université François-Rabelais, Inserm, U930, Tours, France.,Laboratoire de Biochimie, CHRU de Tours, France
| | - P Vourc'h
- Université François-Rabelais, Inserm, U930, Tours, France.,Laboratoire de Biochimie, CHRU de Tours, France
| | | | - G Lenaers
- Département de Biochimie et Génétique, CHU d'Angers, France
| | - C R Andres
- Université François-Rabelais, Inserm, U930, Tours, France.,Laboratoire de Biochimie, CHRU de Tours, France
| | - G Simard
- Institut MITOVASC, UMR CNRS6015-INSERM1083, Université d'Angers, Angers, France.,Département de Biochimie et Génétique, CHU d'Angers, France
| | - P Corcia
- Université François-Rabelais, Inserm, U930, Tours, France.,Centre de Ressources et de Compétences SLA, Service de Neurologie, CHRU Bretonneau, Tours, France.,Fédération des CRCSLA Tours et Limoges, LITORALS, Limoges, France
| | - P Reynier
- Institut MITOVASC, UMR CNRS6015-INSERM1083, Université d'Angers, Angers, France.,Département de Biochimie et Génétique, CHU d'Angers, France
| |
Collapse
|
3
|
Bruno C, Patin F, Bocca C, Nadal-Desbarats L, Bonnier F, Reynier P, Emond P, Vourc'h P, Joseph-Delafont K, Corcia P, Andres CR, Blasco H. The combination of four analytical methods to explore skeletal muscle metabolomics: Better coverage of metabolic pathways or a marketing argument? J Pharm Biomed Anal 2017; 148:273-279. [PMID: 29059617 DOI: 10.1016/j.jpba.2017.10.013] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/01/2017] [Revised: 10/12/2017] [Accepted: 10/13/2017] [Indexed: 01/11/2023]
Abstract
OBJECTIVES Metabolomics is an emerging science based on diverse high throughput methods that are rapidly evolving to improve metabolic coverage of biological fluids and tissues. Technical progress has led researchers to combine several analytical methods without reporting the impact on metabolic coverage of such a strategy. The objective of our study was to develop and validate several analytical techniques (mass spectrometry coupled to gas or liquid chromatography and nuclear magnetic resonance) for the metabolomic analysis of small muscle samples and evaluate the impact of combining methods for more exhaustive metabolite covering. DESIGN AND METHODS We evaluated the muscle metabolome from the same pool of mouse muscle samples after 2 metabolite extraction protocols. Four analytical methods were used: targeted flow injection analysis coupled with mass spectrometry (FIA-MS/MS), gas chromatography coupled with mass spectrometry (GC-MS), liquid chromatography coupled with high-resolution mass spectrometry (LC-HRMS), and nuclear magnetic resonance (NMR) analysis. We evaluated the global variability of each compound i.e., analytical (from quality controls) and extraction variability (from muscle extracts). We determined the best extraction method and we reported the common and distinct metabolites identified based on the number and identity of the compounds detected with low analytical variability (variation coefficient<30%) for each method. Finally, we assessed the coverage of muscle metabolic pathways obtained. RESULTS Methanol/chloroform/water and water/methanol were the best extraction solvent for muscle metabolome analysis by NMR and MS, respectively. We identified 38 metabolites by nuclear magnetic resonance, 37 by FIA-MS/MS, 18 by GC-MS, and 80 by LC-HRMS. The combination led us to identify a total of 132 metabolites with low variability partitioned into 58 metabolic pathways, such as amino acid, nitrogen, purine, and pyrimidine metabolism, and the citric acid cycle. This combination also showed that the contribution of GC-MS was low when used in combination with other mass spectrometry methods and nuclear magnetic resonance to explore muscle samples. CONCLUSION This study reports the validation of several analytical methods, based on nuclear magnetic resonance and several mass spectrometry methods, to explore the muscle metabolome from a small amount of tissue, comparable to that obtained during a clinical trial. The combination of several techniques may be relevant for the exploration of muscle metabolism, with acceptable analytical variability and overlap between methods However, the difficult and time-consuming data pre-processing, processing, and statistical analysis steps do not justify systematically combining analytical methods.
Collapse
Affiliation(s)
- C Bruno
- CHRU de Tours, Laboratoire de Biochimie et Biologie Moléculaire, Tours, France; UMR INSERM U930, Université François Rabelais de Tours, France
| | - F Patin
- CHRU de Tours, Laboratoire de Biochimie et Biologie Moléculaire, Tours, France; UMR INSERM U930, Université François Rabelais de Tours, France
| | - C Bocca
- Institut MITOVASC, CNRS 6015, INSERM U1083, Université d'Angers, Angers, France
| | | | - F Bonnier
- Université François-Rabelais de Tours, Faculté de Pharmacie, EA 6295 Nanomédicaments et Nanosondes, Tours, France
| | - P Reynier
- Institut MITOVASC, CNRS 6015, INSERM U1083, Université d'Angers, Angers, France
| | - P Emond
- UMR INSERM U930, Université François Rabelais de Tours, France
| | - P Vourc'h
- CHRU de Tours, Laboratoire de Biochimie et Biologie Moléculaire, Tours, France; UMR INSERM U930, Université François Rabelais de Tours, France
| | - K Joseph-Delafont
- CHRU de Tours, Laboratoire de Biochimie et Biologie Moléculaire, Tours, France
| | - P Corcia
- UMR INSERM U930, Université François Rabelais de Tours, France; Centre de Ressources et de Compétences SLA, CHU Tours, France; Fédération des Centres de Ressources et de Compétences de Tours et Limoges, Litorals, France
| | - C R Andres
- CHRU de Tours, Laboratoire de Biochimie et Biologie Moléculaire, Tours, France; UMR INSERM U930, Université François Rabelais de Tours, France
| | - H Blasco
- CHRU de Tours, Laboratoire de Biochimie et Biologie Moléculaire, Tours, France; UMR INSERM U930, Université François Rabelais de Tours, France.
| |
Collapse
|
4
|
Delaye JB, Patin F, Piver E, Bruno C, Vasse M, Vourc'h P, Andres CR, Corcia P, Blasco H. Low IDL-B and high LDL-1 subfraction levels in serum of ALS patients. J Neurol Sci 2017; 380:124-127. [PMID: 28870551 DOI: 10.1016/j.jns.2017.07.019] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2017] [Revised: 07/06/2017] [Accepted: 07/16/2017] [Indexed: 12/11/2022]
Abstract
INTRODUCTION Converging evidence highlights that lipid metabolism plays a key role in ALS pathophysiology. Dyslipidemia has been described in ALS patients and may be protective but peripheral lipoprotein subclasses have never been studied. MATERIAL AND METHODS We collected sera from 30 ALS patients and 30 gender and age-matched controls. We analyzed 11 distinct lipoprotein subclasses by linear polyacrylamide gel electrophoresis (Lipoprint, Quantimetrix Corporation, USA). We also measured lipoprotein (a), apolipoprotein B, and apolipoprotein E levels. RESULTS ALS patients had significant higher total cholesterol, HDL-cholesterol, and LDL-cholesterol levels than controls (p<0.0001, p=0.0007, and p=0.0065, respectively). The LDL-1 subfraction concentration was higher (1.03±0.41 vs. 0.71±0.28mmol/L; p=0.0006) and the IDL-B subfraction lower (6.5±2% vs. 8.0±2%; p=0.001) in ALS patients than controls. DISCUSSION Our preliminary work confirmed the association between ALS and dyslipidemia. The low IDL-B levels may explain the hepatic steatosis frequently reported in ALS. The high levels of the cholesterol-rich LDL-1 subfraction is consistent with previously reported hypercholesterolemia. CONCLUSION This study describes, for the first time, the distribution of serum lipoproteins in ALS patients, with low IDL-B and high LDL-1 subfraction level.
Collapse
Affiliation(s)
- J B Delaye
- Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France.
| | - F Patin
- Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France; Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France
| | - E Piver
- Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France; INSERM U966, Faculté de Médecine, Université François Rabelais and CHRU de Tours, Tours, France
| | - C Bruno
- Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France; Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France
| | - M Vasse
- Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France
| | - P Vourc'h
- Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France; Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France
| | - C R Andres
- Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France; Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France
| | - P Corcia
- Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France; Centre SLA, Service de Neurologie, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France
| | - H Blasco
- Laboratoire de Biochimie et de Biologie Moléculaire, Centre Hospitalier Régional Universitaire de Tours, 37044 Tours, France; Unité Mixte de Recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe « Neurogénétique et Neurométabolomique », 37032 Tours, France
| |
Collapse
|
5
|
Maillot F, Veyrat-Durebex C, Debeissat C, Blasco H, Patin F, Henique H, Emond P, Antar C, Herault O. Diminution de l’expression des gènes antioxydants dans les leucocytes des patients adultes atteints de phénylcétonurie. Rev Med Interne 2017. [DOI: 10.1016/j.revmed.2017.03.331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
|
6
|
Bruno C, Dufour-Rainfray D, Patin F, Vourc'h P, Guilloteau D, Maillot F, Labarthe F, Tardieu M, Andres C, Emond P, Blasco H. Erratum to “Validation of amino-acids measurement in dried blood spot by FIA-MS/MS for PKU management” [Clin. Biochem. 49 (2016) 1047–1050]. Clin Biochem 2017; 50:546. [DOI: 10.1016/j.clinbiochem.2017.03.023] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
7
|
Blasco H, Patin F, Molinier S, Vourc'h P, Le Tilly O, Bakkouche S, Andres CR, Meininger V, Couratier P, Corcia P. A decrease in blood cholesterol after gastrostomy could impact survival in ALS. Eur J Clin Nutr 2017; 71:1133-1135. [DOI: 10.1038/ejcn.2017.54] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2016] [Revised: 12/23/2016] [Accepted: 03/20/2017] [Indexed: 11/09/2022]
|
8
|
Blasco H, Patin F, Andres CR, Corcia P, Gordon PH. Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opin Pharmacother 2016; 17:1669-82. [PMID: 27356036 DOI: 10.1080/14656566.2016.1202919] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
INTRODUCTION Amyotrophic lateral sclerosis (ALS), one in a family of age-related neurodegenerative disorders, is marked by predominantly cryptogenic causes, partially elucidated pathophysiology, and elusive treatments. The challenges of ALS are illustrated by two decades of negative drug trials. AREAS COVERED In this article, we lay out the current understanding of disease genesis and physiology in relation to drug development in ALS, stressing important accomplishments and gaps in knowledge. We briefly consider clinical ALS, the ongoing search for biomarkers, and the latest in trial design, highlighting major recent and ongoing clinical trials; and we discuss, in a concluding section on future directions, the prion-protein hypothesis of neurodegeneration and what steps can be taken to end the drought that has characterized drug discovery in ALS. EXPERT OPINION Age-related neurodegenerative disorders are fast becoming major public health problems for the world's aging populations. Several agents offer promise in the near-term, but drug development is hampered by an interrelated cycle of obstacles surrounding etiological, physiological, and biomarkers discovery. It is time for the type of government-funded, public-supported offensive on neurodegenerative disease that has been effective in other fields.
Collapse
Affiliation(s)
- H Blasco
- a Inserm U930, Equipe "neurogénétique et neurométabolomique" , Tours , France.,b Université François-Rabelais, Faculté de Médecine , Tours , France.,c Laboratoire de Biochimie et Biologie Moléculaire , CHRU de Tours , Tours , France
| | - F Patin
- a Inserm U930, Equipe "neurogénétique et neurométabolomique" , Tours , France.,b Université François-Rabelais, Faculté de Médecine , Tours , France.,c Laboratoire de Biochimie et Biologie Moléculaire , CHRU de Tours , Tours , France
| | - C R Andres
- a Inserm U930, Equipe "neurogénétique et neurométabolomique" , Tours , France.,b Université François-Rabelais, Faculté de Médecine , Tours , France.,c Laboratoire de Biochimie et Biologie Moléculaire , CHRU de Tours , Tours , France
| | - P Corcia
- a Inserm U930, Equipe "neurogénétique et neurométabolomique" , Tours , France.,b Université François-Rabelais, Faculté de Médecine , Tours , France.,d Centre SLA, Service de Neurologie , CHRU Bretonneau , Tours , France
| | - P H Gordon
- e Northern Navajo Medical Center , Neurology Unit , Shiprock , NM , USA
| |
Collapse
|
9
|
Blasco H, Patin F, Madji Hounoum B, Gordon PH, Vourc'h P, Andres CR, Corcia P. Metabolomics in amyotrophic lateral sclerosis: how far can it take us? Eur J Neurol 2016; 23:447-54. [PMID: 26822316 DOI: 10.1111/ene.12956] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/31/2015] [Accepted: 12/04/2015] [Indexed: 12/12/2022]
Abstract
Amyotrophic lateral sclerosis (ALS) is the most common adult-onset motor neuron disease. Alongside identification of aetiologies, development of biomarkers is a foremost research priority. Metabolomics is one promising approach that is being utilized in the search for diagnosis and prognosis markers. Our aim is to provide an overview of the principal research in metabolomics applied to ALS. References were identified using PubMed with the terms 'metabolomics' or 'metabolomic' and 'ALS' or 'amyotrophic lateral sclerosis' or 'MND' or 'motor neuron disorders'. To date, nine articles have reported metabolomics research in patients and a few additional studies examined disease physiology and drug effects in patients or models. Metabolomics contribute to a better understanding of ALS pathophysiology but, to date, no biomarker has been validated for diagnosis, principally due to the heterogeneity of the disease and the absence of applied standardized methodology for biomarker discovery. A consensus on best metabolomics methodology as well as systematic independent validation will be an important accomplishment on the path to identifying the long-awaited biomarkers for ALS and to improve clinical trial designs.
Collapse
Affiliation(s)
- H Blasco
- Inserm U930, Tours, France
- Université François-Rabelais, Tours, France
- Laboratoire de Biochimie et Biologie Moléculaire, CHRU de Tours, Tours, France
| | - F Patin
- Inserm U930, Tours, France
- Université François-Rabelais, Tours, France
- Laboratoire de Biochimie et Biologie Moléculaire, CHRU de Tours, Tours, France
| | - B Madji Hounoum
- Inserm U930, Tours, France
- Université François-Rabelais, Tours, France
| | - P H Gordon
- Northern Navajo Medical Center, Shiprock, NM, USA
| | - P Vourc'h
- Inserm U930, Tours, France
- Université François-Rabelais, Tours, France
- Laboratoire de Biochimie et Biologie Moléculaire, CHRU de Tours, Tours, France
| | - C R Andres
- Inserm U930, Tours, France
- Université François-Rabelais, Tours, France
- Laboratoire de Biochimie et Biologie Moléculaire, CHRU de Tours, Tours, France
| | - P Corcia
- Inserm U930, Tours, France
- Université François-Rabelais, Tours, France
- Centre SLA, Service de Neurologie, CHRU Bretonneau, Tours, France
| |
Collapse
|
10
|
Blasco H, Nadal-Desbarats L, Pradat PF, Gordon PH, Madji Hounoum B, Patin F, Veyrat-Durebex C, Mavel S, Beltran S, Emond P, Andres CR, Corcia P. Biomarkers in amyotrophic lateral sclerosis: combining metabolomic and clinical parameters to define disease progression. Eur J Neurol 2015; 23:346-53. [DOI: 10.1111/ene.12851] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2015] [Accepted: 08/03/2015] [Indexed: 12/30/2022]
Affiliation(s)
- H. Blasco
- Université François-Rabelais; Inserm U930; Tours France
- Laboratoire de Biochimie; CHRU de Tours; Tours France
| | | | - P.-F. Pradat
- Centre Référent Maladie Rare SLA; Hôpital de la Pitié-Salpétrière; Paris France
| | | | | | - F. Patin
- Université François-Rabelais; Inserm U930; Tours France
| | | | - S. Mavel
- Université François-Rabelais; Inserm U930; Tours France
| | | | - P. Emond
- Université François-Rabelais; Inserm U930; Tours France
| | - C. R. Andres
- Université François-Rabelais; Inserm U930; Tours France
- Laboratoire de Biochimie; CHRU de Tours; Tours France
| | - P. Corcia
- Université François-Rabelais; Inserm U930; Tours France
- Centre SLA; CHRU de Tours; Tours France
| |
Collapse
|
11
|
Patin F, Corcia P, Madji Hounoum B, Veyrat-Durebex C, Respaud E, Piver E, Benz-de Bretagne I, Vourc'h P, Andres CR, Blasco H. Biological follow-up in amyotrophic lateral sclerosis: decrease in creatinine levels and increase in ferritin levels predict poor prognosis. Eur J Neurol 2015; 22:1385-90. [PMID: 26095828 DOI: 10.1111/ene.12754] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Accepted: 04/27/2015] [Indexed: 01/15/2023]
Abstract
BACKGROUND AND PURPOSE Amyotrophic lateral sclerosis (ALS) is a fatal disorder of the motor neuron system, with a median survival of 2 to 4 years and a wide variety of prognosis. Thus, there is a critical need for diagnosis and prognosis biomarkers to improve the care of patients in routine practice. In this study, we aimed to determine prognostic value of routine biochemical markers in sporadic ALS (SALS). METHODS We retrospectively collected clinical and biological data obtained during the systematic routine monitoring of 216 sporadic ALS patients. The main outcomes were disease duration and annual decline of Revised ALS Functional Rating Scale (ALSFRS-R). Changes to these biological variables over time were assessed, in link with disease progression. RESULTS We found that concentrations of creatinine (P=0.0166) and ferritin (P=0.0306) changed significantly during the progression of ALS. A reduction of creatinine levels and an increase of ferritin levels were associated with disease progression. Multivariate analysis showed that early variation of ferritin was an independent predictive factor of patient survival (P=0.0048). CONCLUSION Changes to ferritin and creatinine levels with time are associated with ALS progression. This is the first study describing the changes to these biological variables during ALS progression.
Collapse
Affiliation(s)
- F Patin
- Unité mixte de recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe Neurogénétique et Neurométabolomique, Tours, France.,Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - P Corcia
- Unité mixte de recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe Neurogénétique et Neurométabolomique, Tours, France.,Centre SLA, Service de Neurologie, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - B Madji Hounoum
- Unité mixte de recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe Neurogénétique et Neurométabolomique, Tours, France
| | - C Veyrat-Durebex
- Unité mixte de recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe Neurogénétique et Neurométabolomique, Tours, France.,Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - E Respaud
- Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - E Piver
- Laboratoire de Biochimie, Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - I Benz-de Bretagne
- Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - P Vourc'h
- Unité mixte de recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe Neurogénétique et Neurométabolomique, Tours, France.,Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - C R Andres
- Unité mixte de recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe Neurogénétique et Neurométabolomique, Tours, France.,Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| | - H Blasco
- Unité mixte de recherche U930, Institut National de la Santé et de la Recherche Médicale, Université François-Rabelais, Equipe Neurogénétique et Neurométabolomique, Tours, France.,Laboratoire de Biochimie et de Biologie Moléculaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire de Tours, Tours, France
| |
Collapse
|